CLINICAL AND PHARMACOECONOMIC REASONABILITY OF USING PROBIOTIC ENTEROCOCCUS STRAIN FOR THE COMPLEX DEVELOPMENTAL CARE PROGRAM FOR PREMATURE INFANTS

Introduction. Possibilities of using probiotic enterococci in premature neonates undergoing inpatient antibacterial therapy remains understudied. The article is aimed at analyzing clinical and pharmacoeconomic reasonability of using probiotic Enterococcus faecium L3 strain in premature infants with very low body weight in the framework of complex inpatient developmental care. Patients and methods. 55 children randomized into 2 groups were observed: the control group (n = 26) was undergoing standard developmental care program, the primary group (n = 29) was introduced liquid probiotic Enterococcus faecium L3 strain (titer — 10⁸ CFU/ml or more) (0.5 ml TID for 14 days) after attaining the enteral feeding volume of 5.0 ml. Results. Analysis of the clinical symptoms characteristic of non-smooth course of developmental care over premature infants helped to reveal higher frequency of infectious complications in the control group children than in the primary group (14 [53.8%] vs. 6 [20.7%]; p < 0.05). Acute food intolerance was observed less frequently in the primary group than in the control group (6 [20.7%] vs. 10 [38.5%], p > 0.05). The primary group's children featured significant decrease in the frequency of monocytosis, positive changes of intestinal microbiotic composition (increase in the amount of bifidum bacteria, lactobacilli, enterococci, decrease in the amount of Clostridium difficile and antibiotic-resistant clinical Klebsiella pneumoniae strains). Conclusion. Favorable outcome of developmental care over premature infants (absence of infectious complications) was less expensive in the primary group's children.

premature infants, very low birth weight, antibiotic therapy, probiotic enterococcus strain, pharmacoeconomic reasonability

1. Surkov D.N., Ivanov D.O., Obolonskii A.I., Kapustina O.G., Volkov D.G., Petrenko Yu.V. Current strategies for nursing preterm infants. Detskaya meditsina Severo-Zapada = Children's Medicine of Northwest. 2012; 3 (1): 4–9.

2. Karavaeva S.A. Diagnosis and clinical features of necrotizing enterocolitis in children. Vestnik khirurgii = Bulletin of surgery. 2002; 161 (4): 41–46.

3. Bin-Nun A., Bromiker R., Wilschanski M. et al. Oral probiotics prevent necrotizing enterocolitis in very low birth weight neonates. Pediatrics. 2005; 147: 192–196.

4. Volyanyuk E.V. Features of antibiotic therapy in preterm infants. Prakticheskaya meditsina = Practical medicine. 2010; 40: 49–52.

5. Lysenko I.M., Barkun G.K., Zhuravleva L.N., Klisho V.E., Misnik O.M. Features colonization resistance neonatal pediatric ward for premature babies in pediatric regional clinical hospitals. Okhrana materinstva i detstva = Maternity and child welfare service. 2008; 1: 105–110.

6. Benis N.A., Samsonova T.V. Clinical and functional characteristics of preterm infants with extremely low and very low birth weight infants and different stages of gestation. Detskaya meditsina Severo-Zapada = Children's Medicine of Northwest. 2012; 3 (1): 26–29.

7. Zakharova I.N., Mazankova L.N. Antibiotikassotsiirovannye diarei u detei: problema i reshenie. Uchebnoe posobie dlya vrachei [Antibiotic-associated Diarrhea in Children: the Problem and the Solution. Manual for Physicians]. Moscow, 2011. 48 p.

8. Sanders M.E., Akkermans L.M.A., Haller D. et al. Safety assessment of probiotics for human use. Gut Microbes. 2010; 1 (3): 164−85.

9. Disbioz kishechnika. Rukovodstvo po diagnostike i lecheniyu. 2-e izd., ispr. i dop. Pod red. E.I. Tkachenko, A.N. Suvorova [Intestinal Dysbiosis. Guidelines for the Diagnosis and Treatment. 2nd ed., rev. and enlarged. Ed. by E.I. Tkachenko, A.N. Suvorov]. St. Petersburg, InformMed, 2009. 276 p.

10. Deshpande G., Rao S., Patole S. Probiotics for prevention of necrotizing enterocolitis in preterm neonates with very low birthweight: a systematic review of randomised controlled trials. Lancet. 2007; 369 (9573): 1614−20.

11. Lund B., Edlund C., Barkholt L. et al. Impact on human intestinal microflora of an Enterococcus faecium probiotic and vancomycin. Scand J Infect Dis. 2000; 32: 627–632.

12. Millar M., Wilks M., Costeloe K. Probiotics for preterm neonates? Arch Dis Child Fetal Neonatal. 2003; 88: F354−F358.

13. Schanler R.J. Probiotics and necrotising enterocolitis in premature neonates. Arch Dis Child Fetal Neonatal. 2006; 91: F395−7.

14. Bondarenko V.M., Suvorov A.N. Simbioticheskie enterokokki i problemy enterokokkovoi opportunisticheskoi infektsii [Symbiotic Enterococci and Problems of Enterococcal Opportunistic Infection]. Moscow, 2007.

15. Gorobchenko V., Kupryashina I., Miller Yu. Clinical and bacteriological efficacy of probiotic Linex in preterm infants. Vrach = The Doctor. 2008; 5: 70.

16. Tarasova E., Yermolenko E., Donets V. et al. The influence of probiotic enetrococci on the microbiota and cytokines expression in rats with dysbiosis induced by antibiotics. Benef Microbes. 2010; 1 (3): 265−70.

17. Kolbin A.S. Kliniko-ekonomicheskie i farmakoepidemiologicheskie aspekty protivogribkovykh sredstv u detei s invazivnym mikozom. Avtoref. dis. …dokt. med. nauk [Clinical, Economic and Pharmacoepidemiological Aspects of Antifungal Agents in Children with Invasive Fungal Infections. Author’s abstract]. St. Petersburg, 2006. 42 p.

18. Shabalov N.P., Ivanov D.O., Shabalova N.N. Neonatal sepsis. Novosti farmakoterapii = News of pharmacotherapy. 2000; 7: 62–69.

19.

20.